In a significant leadership change at Sitryx Therapeutics, a biopharmaceutical firm based in Oxford, UK, Iain Kilty, Ph.D., has been appointed the new Chief Executive Officer effective 2 July 2024. Kilty, previously the Chief Scientific Officer of Sitryx, will also join the company’s Board of Directors. Neil Weir, who led the company for over six years, will transition to the role of President while retaining his Board position. Kilty brings over 25 years of global biopharmaceutical experience, including significant roles at Pfizer, and his leadership is expected to strengthen Sitryx’s discovery pipeline and advance proprietary assets into clinical stages. Weir played a pivotal role in securing a $1.1 billion licensing deal with Eli Lilly and facilitating financings exceeding $75 million. The company recently nominated its first clinical development candidate, SYX-5219 for atopic dermatitis, marking its transition to a clinical-stage organization. Sitryx’s Chairman, Pierre Legault, praised both Weir and Kilty for their contributions and leadership in immunometabolism research.

Biopharmaceutical, Private Equity,United Kingdom, Global